All In Biotech

Drug Trial Radar · NCT04088721

Tolerability and Potential Efficacy of AD17002 in Subjects With Allergic Rhinitis

A Ib/IIa Randomized, Placebo Controlled, Intranasal Administration Study on Safety, Tolerability and Potential Efficacy of AD17002 in Subjects With House Dust Mite (HDM) Allergic Rhinitis

Last checked: Nov 19, 2026Latest source record: Sep 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

48

Actual

Start

Mar 26, 2019

Primary completion

Jul 30, 2020

Study completion Dec 11, 2020

Sponsor

Lead sponsor
Advagene Biopharma Co. Ltd.Industry
Sponsor type
Industry
Collaborators
Clinipace Worldwide; Taipei Medical University
First posted
Sep 13, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years, up to 49 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A single center, double-blind, randomized, dose-escalation study to assess the safety, tolerability and efficacy of 3 doses of AD17002 in comparison to placebo. Subjects will be randomized at 3:1 ratios in each of 3 cohorts to receive AD17002 or placebo.

Conditions

  • Allergic Rhinitis

Interventions

  • AD17002Biological

    LTh(αK) as immunomodulator

  • Formulation BufferOther

    Formulation buffer

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerance of AD17002 treatments in patients with HDM allergy as measured by incidence of adverse eventsTime frame: up to 51 days.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Taipei Medical University

    Taipei, Taiwan, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.